A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-03

Study Completion Date

2023-09-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of JNJ-64304500 as add-on therapy to standard of care (SOC) biologic treatment with anti-tumor necrosis factor alpha or anti-interleukin 12/23 inhibitors in participants with active Crohn's disease in response but not remission to SOC biologic therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

NCT02877134

Crohn Disease

COMPLETED PHASE2

A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease

NCT04102111

Crohn Disease

TERMINATED PHASE2

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

NCT03464136

Crohn Disease

COMPLETED PHASE3

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

NCT02065570

Crohn's Disease

COMPLETED PHASE3

Remission in Subjects With Crohn's Disease, 1 Year Phase

NCT00055497

Crohn's Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Biologic agents such as anti-tumor necrosis factor (TNF) and interleukin (IL)-12/23 antagonists have become the standard of care (SOC) in the treatment of patients with Crohn's disease. However, many patients fail to fully respond to treatment. This study will evaluate the efficacy of 10 week add on treatment with JNJ-64304500, compared to placebo, in patients taking SOC anti-TNF or anti-IL12/23 biologics. The study consists of a screening phase (up to 8 weeks); treatment phase (up to 12 weeks and follow-up phase (up to 16 weeks after the last administration of study agent). The total study duration will be up to 34 weeks. Key safety assessments include adverse events, clinical laboratory tests (hematology and chemistry), vital signs, monitoring for injection-site and hypersensitivity reactions, and early detection of active tuberculosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1- Standard of Care (SOC) Biological Therapy: Adalimumab

Participants will receive JNJ-64304500 Dose 1 or matching placebo subcutaneous (SC) injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to adalimumab or its biosimilar as SOC therapy.

Group Type EXPERIMENTAL

JNJ-64304500

Intervention Type DRUG

JNJ-64304500 will be administered as SC injection.

Placebo

Intervention Type DRUG

Matching placebo will be administered as SC injection.

Adalimumab

Intervention Type DRUG

Adalimumab will be administered as SOC biological therapy.

Group 2: SOC Biological Therapy: Ustekinumab

Participants will receive JNJ-64304500 Dose 1 or matching placebo SC injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to ustekinumab as SOC therapy.

Group Type EXPERIMENTAL

JNJ-64304500

Intervention Type DRUG

JNJ-64304500 will be administered as SC injection.

Placebo

Intervention Type DRUG

Matching placebo will be administered as SC injection.

Ustekinumab

Intervention Type DRUG

Ustekinumab will be administered as SOC biological therapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JNJ-64304500

JNJ-64304500 will be administered as SC injection.

Intervention Type DRUG

Placebo

Matching placebo will be administered as SC injection.

Intervention Type DRUG

Adalimumab

Adalimumab will be administered as SOC biological therapy.

Intervention Type DRUG

Ustekinumab

Ustekinumab will be administered as SOC biological therapy.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have confirmed clinical diagnosis of Crohn's disease or fistulizing Crohn's disease of at least 3 months' duration
* Initiated standard of care (SOC) biologic therapy for at least 12 uninterrupted weeks (including the induction dose) prior to Week 0 and agree to continue to maintain their SOC biologic with no change in dose level or interruption for the duration of the study. Adalimumab (including HUMIRA or an equivalent biosimilar which could include: HULIO, HYRIMOZ, IMRALDI, or AMGEVITA) at maintenance dose of 40 milligram (mg) subcutaneous (SC) every 2 weeks (q2w) plus minus (+ -) 4 days or Ustekinumab at maintenance dose of 90 mg SC every 8 weeks (q8w) + - 7 days
* Have active Crohn's disease (CD), with a baseline crohn's disease activity index (CDAI) score of greater than or equal to (\>=) 180 but less than or equal to (\<=) 400
* Participant with a family history of colorectal cancer, personal history of increased colorectal cancer risk, age greater than (\>) 50 years, or other known risk factor must be up-to-date on colorectal cancer surveillance
* Participant who has had extensive colitis for \>=8 years, or disease limited to the left side of the colon for \>=12 years, must either have had a colonoscopy to assess for the presence of dysplasia within 1 year before the first administration of study agent or a colonoscopy to assess for the presence of malignancy at the screening visit, with no evidence of malignancy
* A woman of childbearing potential must have a negative highly sensitive serum (beta- human chorionic gonadotropin \[beta-hCG\]) pregnancy test result at screening and a negative urine pregnancy test result at Week 0 and throughout the study

Exclusion Criteria

* Has complications of Crohn's disease as defined in study protocol
* Currently has or is suspected to have an abscess
* Concomitant or previous medical therapies received: has previously demonstrated suboptimal response, loss of response, or intolerance to more than 2 approved advanced therapies
* Concomitant or previous medical therapies received: corticosteroids and 5-aminosalicylic acid (5-ASA) compounds at unstable or above recommended doses are not permitted. Individuals receiving stable doses (oral corticosteroids at a prednisone-equivalent dose at or below 20 mg/day, or 6 mg/day of budesonide, 2.5 mg/day beclomethasone dipropionate, or at or below 5-ASA doses of 1.5 gram (g)/day) or if individuals have been discontinued, for at least 2 weeks before start of first study intervention (Week 0), are permitted
* Concomitant or previous medical therapies received: has received any of the following prescribed medications or therapies within the specified period or has plans to initiate throughout the study: conventional immunomodulators (that is , azathioprine \[AZA\], 6-mercaptopurine \[6 MP\], or methotrexate \[MTX\]) within 4 weeks of first dose of study intervention; oral immunomodulatory agents (example, 6-thioguanine \[6-TG\], cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil, tofacitinib and other Janus kinase \[JAK\] inhibitors \[including investigational JAK inhibitors\]) less than (\<) 6 weeks or within 5 half-lives of agent before first dose of SOC biologic, whichever is longer; all other immunomodulatory biologic agents (including investigational biologics) received within 12 weeks or within 5 half-lives of first dose of SOC biologic, whichever is longer
* Infections or predisposition to infections criteria: has a stool culture or other examination positive for an enteric pathogen, including clostridium difficile toxin, in the last 4 months unless a repeat examination is negative and there are no signs of ongoing infection with that pathogen
* Has a transplanted organ (with exception of a corneal transplant that needs to have occurred \> 12 weeks before screening)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No